{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:59Z","timestamp":1787003819487,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NO. 82160927, 82274610, 82260957"],"award-info":[{"award-number":["NO. 82160927, 82274610, 82260957"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guizhou Higher Education Institutions Chinese Medicine and Ethnic Medicine to Prevent and Control Tumor Medical Translational Engineering Research Center of Guizhou Education and Technology","award":["[2023] No.037"],"award-info":[{"award-number":["[2023] No.037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Studies suggest a possible association between Epstein-Barr virus (EBV) infection and bladder cancer (BCa) risk, though this remains unclear. Secreted frizzled-related protein (sFRP) is also linked to BCa, with some DNA viruses potentially regulating its expression. This study used Mendelian randomization (MR) and colocalization analysis to explore the causal relationship between EBV infection, BCa risk, and the mediating role of sFRP. We first performed a two-sample MR study to assess the causal relationship between 5 EBV-related antibodies (AEB-IgG, EA-D, EBNA-1, VCA-p18, ZEBRA) and BCa using the Finnish Consortium\u2019s R11 dataset, validated with R10. Reverse MR analysis followed. For significant results, multivariable MR (MVMR) was applied to adjust for confounding risk factors. A two-step MR explored the potential mediating role of 3 sFRPs (sFRP1, sFRP2, sFRP3) between positive exposures and BCa. Colocalization analysis were conducted for positive exposures, mediators, and BCa, with multiple sensitivity analyses confirming the robustness of the results. The two-sample Mendelian randomization study found that EBNA-1 (OR = 1.15, 95% CI: 1.01\u20131.30;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.039) and VCA-p18 (OR = 1.36, 95% CI: 1.13\u20131.64;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001) may increase BCa risk, with only VCA-p18 (P_fdr = 0.006) showing a significant effect after False Discovery Rate (FDR) correction. The Finnish Consortium R10 replication study yielded similar results, and reverse MR analysis did not suggest reverse causality. After MVMR adjusted for relevant confounders, VCA-p18 (OR = 1.40, 95% CI: 1.13\u20131.74;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002) still significantly increased BCa risk. Two-step MR identified sFRP2 as a mediator, with VCA-p18 down-regulating sFRP2 expression to elevate BCa risk. Colocalization analysis suggested a shared causal variant (nearby gene HLA-DQA1) between VCA-p18 and BCa (PPH4 = 65.44%). Multiple sensitivity analyses confirmed the robustness of the results. Our study suggests that EBV infection (VCA-p18 antibody) may increase the risk of BCa by lowering sFRP2 levels. Additionally, EBNA-1 antibodies may also contribute to an elevated risk of BCa. We hope these findings will provide new insights for future research on the association between EBV and BCa.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-91594-9","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T22:36:53Z","timestamp":1740695813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SFRP2 mediates Epstein-Barr virus and bladder cancer risk: a Mendelian randomization study and colocalization analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Jian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changpu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"91594_CR1","doi-asserted-by":"crossref","unstructured":"1. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 74, 229\u2013263 (2024). https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"91594_CR2","doi-asserted-by":"crossref","unstructured":"2. Zhao, X., Wang, Y. & Liang, C. Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis. International urology and nephrology 54, 1169\u20131185 (2022). https:\/\/doi.org\/10.1007\/s11255-022-03173-w","DOI":"10.1007\/s11255-022-03173-w"},{"key":"91594_CR3","doi-asserted-by":"crossref","unstructured":"3. Dyrskj\u00f8t, L. et al. Bladder cancer. Nature reviews. Disease primers 9, 58 (2023). https:\/\/doi.org\/10.1038\/s41572-023-00468-9","DOI":"10.1038\/s41572-023-00468-9"},{"key":"91594_CR4","doi-asserted-by":"crossref","unstructured":"4. Turati, F. et al. Diabetes mellitus and the risk of bladder cancer: an Italian case\u2013control study. British journal of cancer 113, 127\u2013130 (2015). https:\/\/doi.org\/10.1038\/bjc.2015.178","DOI":"10.1038\/bjc.2015.178"},{"key":"91594_CR5","doi-asserted-by":"crossref","unstructured":"5. Dokanei, S., Minai-Tehrani, D., Moghoofei, M. & Rostamian, M. Investigating the relationship between Epstein-Barr virus infection and gastric cancer: A systematic review and meta-analysis. Health Sci Rep 7, e1976 (2024). https:\/\/doi.org\/10.1002\/hsr2.1976","DOI":"10.1002\/hsr2.1976"},{"key":"91594_CR6","doi-asserted-by":"crossref","unstructured":"6. Epstein, M. A., Achong, B. G. & Barr, Y. M. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT\u2019S LYMPHOMA. Lancet (London, England) 1, 702\u2013703 (1964). https:\/\/doi.org\/10.1016\/s0140-6736(64)91524-7","DOI":"10.1016\/S0140-6736(64)91524-7"},{"key":"91594_CR7","doi-asserted-by":"crossref","unstructured":"7. Zhou, Z. et al. VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11, e2308765 (2024). https:\/\/doi.org\/10.1002\/advs.202308765","DOI":"10.1002\/advs.202308765"},{"key":"91594_CR8","doi-asserted-by":"crossref","unstructured":"8. Yang, J., Liu, Z., Zeng, B., Hu, G. & Gan, R. Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett 495, 191\u2013199 (2020). https:\/\/doi.org\/10.1016\/j.canlet.2020.09.019","DOI":"10.1016\/j.canlet.2020.09.019"},{"key":"91594_CR9","doi-asserted-by":"crossref","unstructured":"9. Leonard, S. et al. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin\u2019s lymphoma. J Virol 85, 9568\u20139577 (2011). https:\/\/doi.org\/10.1128\/jvi.00468-11","DOI":"10.1128\/JVI.00468-11"},{"key":"91594_CR10","doi-asserted-by":"crossref","unstructured":"10. Jalilian, S. & Bastani, M. N. From virus to cancer: Epstein-Barr virus miRNA connection in Burkitt\u2019s lymphoma. Infect Agent Cancer 19, 54 (2024). https:\/\/doi.org\/10.1186\/s13027-024-00615-1","DOI":"10.1186\/s13027-024-00615-1"},{"key":"91594_CR11","doi-asserted-by":"crossref","unstructured":"11. Gazzaniga, P. et al. Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. Journal of medical virology 55, 262\u2013267 (1998). https:\/\/doi.org\/10.1002\/(sici)1096-9071(199808)55:4<262::aid-jmv2>3.0.co;2-z","DOI":"10.1002\/(SICI)1096-9071(199808)55:4<262::AID-JMV2>3.0.CO;2-Z"},{"key":"91594_CR12","doi-asserted-by":"crossref","unstructured":"12. Abe, T. et al. Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers. Int J Urol 15, 429\u2013434 (2008). https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02030.x","DOI":"10.1111\/j.1442-2042.2008.02030.x"},{"key":"91594_CR13","doi-asserted-by":"crossref","unstructured":"13. Chuang, K. L. et al. Epstein-Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas. BJU Int 107, 150\u2013154 (2011). https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09474.x","DOI":"10.1111\/j.1464-410X.2010.09474.x"},{"key":"91594_CR14","doi-asserted-by":"crossref","unstructured":"14. Loran, O. B. et al. [High oncogenic risk human papillomavirus and urinary bladder cancer]. Urologiia, 60\u201366 (2017). https:\/\/doi.org\/10.18565\/urol.2017.3.60-66","DOI":"10.18565\/urol.2017.3.60-66"},{"key":"91594_CR15","unstructured":"15. Kosova, I. V. et al. [A prognostic value of level of antiviral antibodies in the development of recurrence of bladder cancer]. Urologiia, 86\u201394 (2018)."},{"key":"91594_CR16","doi-asserted-by":"crossref","unstructured":"16. Shi, Y., He, B., You, L. & Jablons, D. M. Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 28, 1499\u20131504 (2007). https:\/\/doi.org\/10.1111\/j.1745-7254.2007.00692.x","DOI":"10.1111\/j.1745-7254.2007.00692.x"},{"key":"91594_CR17","doi-asserted-by":"crossref","unstructured":"17. Wissmann, C. et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201, 204\u2013212 (2003). https:\/\/doi.org\/10.1002\/path.1449","DOI":"10.1002\/path.1449"},{"key":"91594_CR18","doi-asserted-by":"crossref","unstructured":"18. Stoehr, R. et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 84, 465\u2013478 (2004). https:\/\/doi.org\/10.1038\/labinvest.3700068","DOI":"10.1038\/labinvest.3700068"},{"key":"91594_CR19","doi-asserted-by":"crossref","unstructured":"19. Lai, H. Y. et al. High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis. Frontiers in oncology 12, 834249 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.834249","DOI":"10.3389\/fonc.2022.834249"},{"key":"91594_CR20","doi-asserted-by":"crossref","unstructured":"20. Rogler, A. et al. Functional analyses and prognostic significance of SFRP1 expression in bladder cancer. J Cancer Res Clin Oncol 141, 1779\u20131790 (2015). https:\/\/doi.org\/10.1007\/s00432-015-1942-1","DOI":"10.1007\/s00432-015-1942-1"},{"key":"91594_CR21","unstructured":"21. Rogler, A. et al. Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk. Int J Clin Exp Pathol 6, 1984\u20131998 (2013)."},{"key":"91594_CR22","doi-asserted-by":"crossref","unstructured":"22. Marsit, C. J., McClean, M. D., Furniss, C. S. & Kelsey, K. T. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. International journal of cancer 119, 1761\u20131766 (2006). https:\/\/doi.org\/10.1002\/ijc.22051","DOI":"10.1002\/ijc.22051"},{"key":"91594_CR23","doi-asserted-by":"crossref","unstructured":"23. Al-Shabanah, O. A. et al. Methylation of SFRPs and APC genes in ovarian cancer infected with high risk human papillomavirus. Asian Pac J Cancer Prev 15, 2719\u20132725 (2014). https:\/\/doi.org\/10.7314\/apjcp.2014.15.6.2719","DOI":"10.7314\/APJCP.2014.15.6.2719"},{"key":"91594_CR24","doi-asserted-by":"crossref","unstructured":"24. Quan, H. et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene 33, 2826\u20132835 (2014). https:\/\/doi.org\/10.1038\/onc.2013.225","DOI":"10.1038\/onc.2013.225"},{"key":"91594_CR25","doi-asserted-by":"crossref","unstructured":"25. Wang, X. et al. Methylation and aberrant expression of the Wnt antagonist secreted Frizzled-related protein 1 in bladder cancer. Oncology letters 4, 334\u2013338 (2012). https:\/\/doi.org\/10.3892\/ol.2012.713","DOI":"10.3892\/ol.2012.713"},{"key":"91594_CR26","doi-asserted-by":"crossref","unstructured":"26. Tsai, C. N., Tsai, C. L., Tse, K. P., Chang, H. Y. & Chang, Y. S. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proceedings of the National Academy of Sciences of the United States of America 99, 10084\u201310089 (2002). https:\/\/doi.org\/10.1073\/pnas.152059399","DOI":"10.1073\/pnas.152059399"},{"key":"91594_CR27","doi-asserted-by":"crossref","unstructured":"27. Hino, R. et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer research 69, 2766\u20132774 (2009). https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3070","DOI":"10.1158\/0008-5472.CAN-08-3070"},{"key":"91594_CR28","doi-asserted-by":"crossref","unstructured":"28. Bowden, J. & Holmes, M. V. Meta-analysis and Mendelian randomization: A review. Res Synth Methods 10, 486\u2013496 (2019). https:\/\/doi.org\/10.1002\/jrsm.1346","DOI":"10.1002\/jrsm.1346"},{"key":"91594_CR29","doi-asserted-by":"crossref","unstructured":"29. Guo, X. et al. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncol 93, 85\u201390 (2019). https:\/\/doi.org\/10.1016\/j.oraloncology.2019.04.024","DOI":"10.1016\/j.oraloncology.2019.04.024"},{"key":"91594_CR30","doi-asserted-by":"crossref","unstructured":"30. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. Bmj 362, k601 (2018). https:\/\/doi.org\/10.1136\/bmj.k601","DOI":"10.1136\/bmj.k601"},{"key":"91594_CR31","doi-asserted-by":"crossref","unstructured":"31. Butler-Laporte, G. et al. Genetic Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A Genome-Wide and HLA Association Study. Open Forum Infect Dis 7, ofaa450 (2020). https:\/\/doi.org\/10.1093\/ofid\/ofaa450","DOI":"10.1093\/ofid\/ofaa450"},{"key":"91594_CR32","doi-asserted-by":"crossref","unstructured":"32. Julian, T. H. et al. Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular degeneration. Elife 12 (2023). https:\/\/doi.org\/10.7554\/eLife.82546","DOI":"10.7554\/eLife.82546"},{"key":"91594_CR33","doi-asserted-by":"crossref","unstructured":"33. Palmer, T. M. et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol 173, 1392\u20131403 (2011). https:\/\/doi.org\/10.1093\/aje\/kwr026","DOI":"10.1093\/aje\/kwr026"},{"key":"91594_CR34","doi-asserted-by":"crossref","unstructured":"34. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44, 512\u2013525 (2015). https:\/\/doi.org\/10.1093\/ije\/dyv080","DOI":"10.1093\/ije\/dyv080"},{"key":"91594_CR35","doi-asserted-by":"crossref","unstructured":"35. Budu-Aggrey, A. & Paternoster, L. Research Techniques Made Simple: Using Genetic Variants for Randomization. J Invest Dermatol 139, 1416\u20131421.e1411 (2019). https:\/\/doi.org\/10.1016\/j.jid.2019.03.1138","DOI":"10.1016\/j.jid.2019.03.1138"},{"key":"91594_CR36","doi-asserted-by":"crossref","unstructured":"36. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 40, 304\u2013314 (2016). https:\/\/doi.org\/10.1002\/gepi.21965","DOI":"10.1002\/gepi.21965"},{"key":"91594_CR37","doi-asserted-by":"crossref","unstructured":"37. Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am J Hum Genet 108, 1251\u20131269 (2021). https:\/\/doi.org\/10.1016\/j.ajhg.2021.05.014","DOI":"10.1016\/j.ajhg.2021.05.014"},{"key":"91594_CR38","doi-asserted-by":"crossref","unstructured":"38. Yu, K. et al. Assessment of bidirectional relationships between brain imaging-derived phenotypes and stroke: a Mendelian randomization study. BMC medicine 21, 271 (2023). https:\/\/doi.org\/10.1186\/s12916-023-02982-9","DOI":"10.1186\/s12916-023-02982-9"},{"key":"91594_CR39","doi-asserted-by":"crossref","unstructured":"39. Marsit, C. J. et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer research 65, 7081\u20137085 (2005). https:\/\/doi.org\/10.1158\/0008-5472.Can-05-0267","DOI":"10.1158\/0008-5472.CAN-05-0267"},{"key":"91594_CR40","doi-asserted-by":"crossref","unstructured":"40. Zuber, V. et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am J Hum Genet 109, 767\u2013782 (2022). https:\/\/doi.org\/10.1016\/j.ajhg.2022.04.001","DOI":"10.1016\/j.ajhg.2022.04.001"},{"key":"91594_CR41","doi-asserted-by":"crossref","unstructured":"41. Chen, J. et al. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses. EBioMedicine 89, 104494 (2023). https:\/\/doi.org\/10.1016\/j.ebiom.2023.104494","DOI":"10.1016\/j.ebiom.2023.104494"},{"key":"91594_CR42","doi-asserted-by":"crossref","unstructured":"42. Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nature reviews. Cancer 4, 757\u2013768 (2004). https:\/\/doi.org\/10.1038\/nrc1452","DOI":"10.1038\/nrc1452"},{"key":"91594_CR43","doi-asserted-by":"crossref","unstructured":"43. Karsten, C. B. et al. Evolution of functional antibodies following acute Epstein-Barr virus infection. PLoS Pathog 18, e1010738 (2022). https:\/\/doi.org\/10.1371\/journal.ppat.1010738","DOI":"10.1371\/journal.ppat.1010738"},{"key":"91594_CR44","doi-asserted-by":"crossref","unstructured":"44. Farrell, P. J. Epstein-Barr Virus and Cancer. Annual review of pathology 14, 29\u201353 (2019). https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-013023","DOI":"10.1146\/annurev-pathmechdis-012418-013023"},{"key":"91594_CR45","doi-asserted-by":"crossref","unstructured":"45. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860\u2013867 (2002). https:\/\/doi.org\/10.1038\/nature01322","DOI":"10.1038\/nature01322"},{"key":"91594_CR46","doi-asserted-by":"crossref","unstructured":"46. Urbaczek, A. C. et al. Influence of Fc\u03b3RIIIb polymorphism on its ability to cooperate with Fc\u03b3RIIa and CR3 in mediating the oxidative burst of human neutrophils. Hum Immunol 75, 785\u2013790 (2014). https:\/\/doi.org\/10.1016\/j.humimm.2014.05.011","DOI":"10.1016\/j.humimm.2014.05.011"},{"key":"91594_CR47","doi-asserted-by":"crossref","unstructured":"47. Shiina, T., Hosomichi, K., Inoko, H. & Kulski, J. K. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 54, 15\u201339 (2009). https:\/\/doi.org\/10.1038\/jhg.2008.5","DOI":"10.1038\/jhg.2008.5"},{"key":"91594_CR48","doi-asserted-by":"crossref","unstructured":"48. Chen, P. C., Tsai, E. M., Er, T. K., Chang, S. J. & Chen, B. H. HLA-DQA1 and -DQB1 allele typing in southern Taiwanese women with breast cancer. Clin Chem Lab Med 45, 611\u2013614 (2007). https:\/\/doi.org\/10.1515\/cclm.2007.132","DOI":"10.1515\/CCLM.2007.132"},{"key":"91594_CR49","doi-asserted-by":"crossref","unstructured":"49. Spraggs, C. F. et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29, 667\u2013673 (2011). https:\/\/doi.org\/10.1200\/jco.2010.31.3197","DOI":"10.1200\/JCO.2010.31.3197"},{"key":"91594_CR50","doi-asserted-by":"crossref","unstructured":"50. Tsai, S. C., Sheen, M. C. & Chen, B. H. Association between HLA-DQA1, HLA-DQB1 and oral cancer. Kaohsiung J Med Sci 27, 441\u2013445 (2011). https:\/\/doi.org\/10.1016\/j.kjms.2011.06.003","DOI":"10.1016\/j.kjms.2011.06.003"},{"key":"91594_CR51","doi-asserted-by":"crossref","unstructured":"51. Zhou, J., Xie, T., Shan, H. & Cheng, G. HLA-DQA1 expression is associated with prognosis and predictable with radiomics in breast cancer. Radiat Oncol 18, 117 (2023). https:\/\/doi.org\/10.1186\/s13014-023-02314-4","DOI":"10.1186\/s13014-023-02314-4"},{"key":"91594_CR52","doi-asserted-by":"crossref","unstructured":"52. Nojima, M. et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26, 4699\u20134713 (2007). https:\/\/doi.org\/10.1038\/sj.onc.1210259","DOI":"10.1038\/sj.onc.1210259"},{"key":"91594_CR53","doi-asserted-by":"crossref","unstructured":"53. Xie, Q. et al. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. International journal of cancer 135, 635\u2013646 (2014). https:\/\/doi.org\/10.1002\/ijc.28697","DOI":"10.1002\/ijc.28697"},{"key":"91594_CR54","doi-asserted-by":"crossref","unstructured":"54. Hu, H. et al. Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer. Pathol Oncol Res 25, 567\u2013575 (2019). https:\/\/doi.org\/10.1007\/s12253-018-0505-6","DOI":"10.1007\/s12253-018-0505-6"},{"key":"91594_CR55","doi-asserted-by":"crossref","unstructured":"55. Qu, Y., Dang, S. & Hou, P. Gene methylation in gastric cancer. Clin Chim Acta 424, 53\u201365 (2013). https:\/\/doi.org\/10.1016\/j.cca.2013.05.002","DOI":"10.1016\/j.cca.2013.05.002"},{"key":"91594_CR56","doi-asserted-by":"crossref","unstructured":"56. Peng, C., Xiao, X., Kang, B., He, S. & Li, J. Serum secreted frizzled-related protein 5 levels differentially decrease in patients with hepatitis B virus-associated chronic infection and hepatocellular carcinoma. Oncology letters 8, 1340\u20131344 (2014). https:\/\/doi.org\/10.3892\/ol.2014.2256","DOI":"10.3892\/ol.2014.2256"},{"key":"91594_CR57","doi-asserted-by":"crossref","unstructured":"57. Garai-Ibabe, G. et al. Label free and amplified detection of cancer marker EBNA-1 by DNA probe based biosensors. Biosens Bioelectron 30, 272\u2013275 (2011). https:\/\/doi.org\/10.1016\/j.bios.2011.09.025","DOI":"10.1016\/j.bios.2011.09.025"},{"key":"91594_CR58","doi-asserted-by":"crossref","unstructured":"58. Wilson, J. B., Bell, J. L. & Levine, A. J. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo j 15, 3117\u20133126 (1996).","DOI":"10.1002\/j.1460-2075.1996.tb00674.x"},{"key":"91594_CR59","doi-asserted-by":"crossref","unstructured":"59. Lu, J. et al. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 410, 64\u201375 (2011). https:\/\/doi.org\/10.1016\/j.virol.2010.10.029","DOI":"10.1016\/j.virol.2010.10.029"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91594-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T22:37:22Z","timestamp":1740695842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91594-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91594"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91594-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each of the studies contributing to the GWAS obtained informed consent from study participants and ethical approval for data collection and analysis. Our study complied with all relevant ethical regulations, including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"7118"}}